Products we own, delivered through licenses we hold, into channels where we have a contracting advantage.
Makes the drug under an FDA approval and sells almost entirely to wholesalers.
Stateline, the Vicapsys distributor, buys the product, takes ownership of it, stores and delivers it, earning a margin on every unit.
VicapsysPharmacy, hospital, clinic, infusion center or government facility.
Every unit tracked from factory to dispenser under the federal Drug Supply Chain Security Act.
Three companies handle more than 90% of U.S. drug distribution and are projected to book $933 billion of revenue in 2026.2 Their model is built for national pharmacy chains and large health systems. Rural, tribal, Indian Health Service, Veterans Affairs, Department of Defense and Puerto Rico accounts are small, compliance-heavy and far from their distribution centers. Vicapsys is the wholesale drug distributor for those channels.
U.S. net spending on medicines was $487 billion in 2024.1 Veterans Affairs and the Defense Health Program spend more than $21 billion a year on pharmaceuticals between them.3 4 Sources are listed on the platform page.
DSCSA-compliant, licensed by the Puerto Rico Department of Health for drug wholesale and for biological products. 400+ accounts, 15,000+ SKUs and all 50 states on the Drugzone title model.
Teaming agreement with a tribally owned, SBA-certified 8(a) partner: non-competed and set-aside federal awards at the Indian Health Service, Veterans Affairs and the Department of Defense.
Nitroglycerin lingual aerosol for angina, off the market since 2022 for reasons unrelated to safety or efficacy. Definitive purchase agreement signed; relaunch under way.
Alongside the three parts: brand-name specialty and oncology supply for Puerto Rico at DACO pricing through the Stateline account base, and VICAPSYN™, the company's legacy biotechnology program under an exclusive license from Massachusetts General Hospital.
Because the NDA remains approved, the relaunch needs stability, fill and validation work, not new clinical trials.
NitroMist (NDA 021780) was approved in 2006, marketed in the U.S. from 2011 and voluntarily discontinued in 2022 by a prior owner for reasons unrelated to safety or efficacy. Under prior ownership it reached peak sales of about US$40 million a year, under the direction of Humberto Borque, who now leads the relaunch for Vicapsys.
An alcohol-free, propellant-driven metered dose designed to withstand freeze-thaw and heat cycling in field, EMS, military and rural storage, where conventional nitrates fail. It returns as a deliberately limited-distribution product on a narrow formulary, through Stateline's accounts and the federal and tribal channel.
Replacing the insulin-producing cells that type 1 diabetes destroys is now possible, but today's leading cell therapy requires lifelong immunosuppression.
The market leader's attempt to avoid that with an encapsulation device was discontinued in 2025. VICAPSYN encapsulates islet cells in a matrix that releases CXCL12, a signal that turns immune cells away from the graft: in published work, encapsulated cells kept working in immunocompetent mice for more than 150 days with no systemic immunosuppression, and in a 2023 primate pilot, CXCL12 microbeads holding pig islets were retrieved at six months without foreign-body response, fibrosis or systemic immunosuppression.
The next step is a cGMP-manufactured product and a proof-of-concept study in non-human primates. The operating business comes first; the program is retained for the optionality it gives shareholders.
Clinics and hospitals outside the metropolitan delivery routes the national wholesalers are built around.
Tribally operated health programs, reached through a certified 8(a) teaming partner.
Federal facilities serving American Indian and Alaska Native communities.
The largest integrated health system in the United States.
Military treatment facilities and field medicine, where storage conditions are demanding.
400+ accounts served today from San Juan under Stateline's licenses.
Vicapsys Life Sciences, Inc. is a public pharmaceutical platform company, headquartered in Miami, Florida, with operations in San Juan, Puerto Rico. On September 3, 2026 it completed its merger with Stateline Distributors of Puerto Rico, Inc., a licensed wholesale drug distributor that is now a wholly owned subsidiary. The company serves rural, tribal, Indian Health Service, Veterans Affairs, Department of Defense and Puerto Rico markets by combining licensed distribution, federal contracting access and owned FDA-approved products.
The immune-isolation technology for islet cell transplantation in type 1 diabetes remains an active asset, integrated with the Company's Indian Health Service strategy; partnerships in Argentina are being explored.
Read the releaseA new identity for the parent company and its Stateline subsidiary, the first of several housekeeping steps following the merger.
Read the announcementEight advisors covering federal channels, manufacturing and quality, oncology, finance, brand, institutional purchasing and tribal contracting.
Read the announcementVicapsys Life Sciences, Inc. is a public company. Its shares trade on OTC Markets, where its disclosure statements and announcements are posted.
